AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sialidase-3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UQ49

UPID:

NEUR3_HUMAN

Alternative names:

Ganglioside sialidasedis; Membrane sialidase; N-acetyl-alpha-neuraminidase 3

Alternative UPACC:

Q9UQ49; A8K327; Q9NQE1

Background:

Sialidase-3, also known as Ganglioside sialidase, Membrane sialidase, and N-acetyl-alpha-neuraminidase 3, is a crucial enzyme in the catabolism of glycolipids, glycoproteins, and oligosaccharides. It efficiently catalyzes the hydrolytic cleavage of terminal sialic acids, particularly impacting gangliosides such as GD1a, GM3, and GD3. This enzyme plays a pivotal role in cellular processes by modulating the ganglioside content of lipid bilayers and interacting directly with signaling receptors like EGFR, thereby influencing transmembrane signaling and receptor endocytosis.

Therapeutic significance:

Understanding the role of Sialidase-3 could open doors to potential therapeutic strategies. Its involvement in the regulation of key cellular processes, such as EGFR-mediated signaling and receptor trafficking, highlights its potential as a target in diseases where these pathways are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.